Precigen, Inc. (PGEN) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2025. Precigen, Inc. is a commercial-stage biopharmaceutical company focused on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. The reporting period marks a pivotal transition from a development-stage to a commercial-stage company following the August 14, 2025 full FDA approval of Papzimeos (zopapogene imadenovec-drba), the first and only therapy approved for adults with recurrent respiratory papillomatosis (RRP). The company operates a single reporting segment as of Q1 2025, consolidating its Biopharmaceutical and Exemplar (animal research models) operations.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $9.7 million | $3.9 million | +146.7% |
| Product Revenues (Net) | $4.0 million | $0.4 million | >200% |
| Net Loss | $(250.6) million | $(126.2) million | +98.6% (wider) |
| Net Loss Attributable to Common Shareholders | $(429.6) million | $(126.2) million | >200% (wider) |
| Operating Cash Flow | $(87.8) million | $(68.2) million | Increased outflow |
| Cash & Investments (End of Period) | $100.4 million | $97.9 million | Positive |
| Long-Term Debt | $93.2 million (carrying value) | $0 | New Facility |
Note: The significant increase in Net Loss is primarily driven by a $139.5 million non-cash expense related to the change in fair value of warrant liabilities and a $179.0 million non-cash deemed dividend upon the conversion of Series A Preferred Stock.
Material Changes vs. Prior Period
- Commercial Launch: Papzimeos generated $3.4 million in product revenue in Q4 2025, compared to zero in 2024. This was offset by a significant increase in Selling, General, and Administrative (SG&A) expenses ($70.1 million in 2025 vs. $41.3 million in 2024) due to commercial readiness costs, including sales force expansion and marketing.
- R&D Efficiency: Research and Development expenses decreased by 22.1% to $41.3 million, driven by the shutdown of the ActoBio subsidiary and strategic prioritization of the pipeline (pausing PRGN-3005 and PRGN-3007 trials).
- Capital Structure: In September 2025, the company entered a $125 million senior secured term loan facility, drawing $100 million initially. Additionally, all 79,000 shares of Series A Preferred Stock were converted into approximately 54.9 million shares of common stock, resulting in a $179 million deemed dividend charge.
- Impairments: Goodwill impairment charges decreased to $3.9 million in 2025 (related to the Exemplar reporting unit) compared to $7.4 million in 2024. There were no impairments of other noncurrent assets in 2025, compared to $32.9 million in 2024.
Guidance, Outlook, and Risks
Outlook: Management expects future revenue to be primarily generated from Papzimeos sales. The company anticipates gross margins will stabilize between the high 80% and low 90% range once pre-launch inventory is sold. The company believes its existing cash, investments, and anticipated Papzimeos revenue will fund operations for at least one year from the filing date.
Key Risks:
- Commercial Execution: Success is heavily dependent on Papzimeos market acceptance, payer coverage (currently ~215 million lives covered), and manufacturing supply chain stability.
- Liquidity: The company has a history of net losses and an accumulated deficit of $2.3 billion. Future capital requirements are substantial, and additional financing may be required, potentially causing dilution.
- Debt Obligations: The new term loan bears interest at Term SOFR + 6.50% (with a 3.75% floor) and includes restrictive covenants, including minimum net sales and liquidity requirements.
- Pipeline Uncertainty: While Papzimeos is approved, other candidates (PRGN-2009, PRGN-3006) remain in clinical development with uncertain outcomes. Enrollment in PRGN-3005 and PRGN-3007 has been paused.
Investor Verification Checklist
- Papzimeos Sales Velocity: Verify Q4 2025 and Q1 2026 sales figures to assess if commercial uptake meets internal projections of $85 million in pre-launch inventory value.
- Debt Covenant Compliance: Monitor quarterly reports for compliance with the new loan agreement's minimum net sales and liquidity covenants.
- Reimbursement Status: Confirm the status of the European Medicines Agency (EMA) Marketing Authorization Application (MAA) submitted in November 2025 and ongoing payer coverage expansions in the U.S.
- Inventory Valuation: Review the accounting treatment of pre-launch inventory and the realization of gross margins as this inventory is sold in 2026.
- Equity Dilution: Track the impact of the 54.9 million shares issued upon preferred stock conversion and potential future equity raises needed to fund operations.